Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

被引：30

作者：

Dauner, Joseph G. ^{[1
]}

Pan, Yuanji ^{[1
]}

Hildesheim, Allan ^{[2
]}

Harro, Clayton ^{[3
]}

Pinto, Ligia A. ^{[1
]}

机构：

[1] NCI, HPV Immunol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA

[2] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA

[3] Johns Hopkins Univ, Ctr Immunizat Res, Baltimore, MD 21205 USA

来源：

VACCINE | 2010年 / 28卷 / 33期

基金：

美国国家卫生研究院;

关键词：

HPV; VLP; Vaccination; Humoral response; HUMAN-PAPILLOMAVIRUS TYPE-16; VIRUS-LIKE PARTICLES; PROPHYLACTIC VACCINATION; MONOCLONAL-ANTIBODIES; AVIDITY MATURATION; CONJUGATE VACCINE; IMMUNE-RESPONSES; PROTEIN; IMMUNIZATION; INFECTION;

D O I：

10.1016/j.vaccine.2010.06.018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Human papillomavirus (HPV)-specific antibodies are proposed to be the correlate of protection afforded by HPV L1 virus-like particle (VLP) vaccines Previous studies have characterized the systemic antibody response to immunization in terms of both the quantity and the ability to neutralize HPV Here, we have adapted a generalized memory B cell ELISPOT to the HPV16 system and expanded the analysis of the systemic antibody response to include an avidity measurement of HPV 1.1 VIP-specific antibodies We show the results of the memory B cell ELISPOT significantly correlated with IgG and neutralizing antibody titers, but not with the avidity measurement This is the first comprehensive study to correlate a variety of humoral aspects potentially associated with protective immunity following vaccination with a HPV16 L1 VLP vaccine. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：5407 / 5413

页数：7

共 41 条

[1] Maintenance of serological memory by polyclonal activation of human memory B cells [J].

Bernasconi, NL ;

Traggiai, E ;

Lanzavecchia, A .

SCIENCE, 2002, 298 (5601) :2199-2202

[2] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION [J].

BREITBURD, F ;

KIRNBAUER, R ;

HUBBERT, NL ;

NONNENMACHER, B ;

TRINDINHDESMARQUET, C ;

ORTH, G ;

SCHILLER, JT ;

LOWY, DR .

JOURNAL OF VIROLOGY, 1995, 69 (06) :3959-3963

[3] Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies [J].

Christensen, ND ;

Dillner, J ;

Eklund, C ;

Carter, JJ ;

Wipf, GC ;

Reed, CA ;

Cladel, NM ;

Galloway, DA .

VIROLOGY, 1996, 223 (01) :174-184

[4] Cutting edge: Long-term B cell memory in humans after smallpox vaccination [J].

Crotty, S ;

Felgner, P ;

Davies, H ;

Glidewell, J ;

Villarreal, L ;

Ahmed, R .

JOURNAL OF IMMUNOLOGY, 2003, 171 (10) :4969-4973

[5] Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system [J].

Crotty, S ;

Aubert, RD ;

Glidewell, J ;

Ahmed, R .

JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 286 (1-2) :111-122

[6] Quality of the haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular Pertussis/Hib combination vaccines [J].

Denoel, Philippe A. ;

Goldblatt, David ;

de Vleeschauwer, Isabel ;

Jacquet, Jeanne-Marie ;

Pichichero, Michael E. ;

Poolman, Jan T. .

CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (10) :1362-1369

[7] Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine [J].

Dessy, Francis J. ;

Giannini, Sandra L. ;

Bougelet, Catherine A. ;

Kemp, Troy J. ;

David, Marie-Pierre M. ;

Poncelet, Sylviane M. ;

Pinto, Ligia A. ;

Wettendroff, Martine A. .

HUMAN VACCINES, 2008, 4 (06) :425-434

[8] Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years [J].

Einstein, Mark H. ;

Baron, Mira ;

Levin, Myron J. ;

Chatterjee, Archana ;

Edwards, Robert P. ;

Zepp, Fred ;

Carletti, Isabelle ;

Dessy, Francis J. ;

Trofa, Andrew F. ;

Schuind, Anne ;

Dubin, Gary .

HUMAN VACCINES, 2009, 5 (10) :705-719

[9] Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only [J].

Giannini, Sandra L. ;

Hanon, Emmanuel ;

Moris, Philippe ;

Van Mechelen, Marcelle ;

Morel, Sandra ;

Dessy, Francis ;

Fourneau, Marc A. ;

Colau, Brigitte ;

Suzich, Joann ;

Losonksy, Genevieve ;

Martin, Marie-Therese ;

Dubin, Gary ;

Wettendorff, Martine A. .

VACCINE, 2006, 24 (33-34) :5937-5949

[10] Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [J].

Harper, DM ;

Franco, EL ;

Wheeler, C ;

Ferris, DG ;

Jenkins, D ;

Schuind, A ;

Zahaf, T ;

Innis, B ;

Naud, P ;

De Carvalho, NS ;

Roteli-Martins, CM ;

Teixeira, J ;

Blatter, MM ;

Korn, AP ;

Quint, W ;

Dubin, G .

LANCET, 2004, 364 (9447) :1757-1765

← 1 2 3 4 5 →